Reuters logo
BRIEF-Acorda announces positive phase 3 clinical trial results for CVT-301
February 9, 2017 / 11:17 AM / 7 months ago

BRIEF-Acorda announces positive phase 3 clinical trial results for CVT-301

Feb 9 (Reuters) - Acorda Therapeutics Inc

* Acorda therapeutics inc - span-pd trial met primary endpoint

* Acorda therapeutics inc - new drug application (nda) submission planned for q2 2017

* Acorda announces positive phase 3 clinical trial results for cvt-301

* Acorda therapeutics inc - data from two long-term safety studies expected in q1 2017

* Acorda therapeutics inc - cvt-301 showed statistically significant improvement of motor function compared to placebo

* Acorda therapeutics inc - also plans to file a marketing authorization application (maa) in europe by end of 2017 for cvt-301 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below